Oncology Institute (DFPH) Return on Capital Employed (2021 - 2026)

Oncology Institute (DFPH) has reported Return on Capital Employed for 6 consecutive years, with 37.53% the latest figure, recorded in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 37.53%, up 1031.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 37.53% (up 1031.0% YoY), and the FY2025 annual result was 36.92%, up 640.0% from the prior year.
• Return on Capital Employed was 37.53% for Q1 2026 at Oncology Institute, up from 38.73% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 33.72% in Q4 2022 and troughed at 49.24% in Q2 2022.
• Average Return on Capital Employed over 5 years is 43.34%, with a median of 44.18% recorded in 2023.
• Year-over-year, Return on Capital Employed sank 4452 bps in 2022 and soared 1031 bps in 2026.
• Over 5 years, Return on Capital Employed stood at 33.72% in 2022, then retreated by 28 bps to 43.02% in 2023, then slipped by 13 bps to 48.59% in 2024, then advanced by 20 bps to 38.73% in 2025, then increased by 3 bps to 37.53% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 37.53% in Q1 2026, 38.73% in Q4 2025, and 42.76% in Q3 2025.